Investing.comCodex · 实盘不做把握 8/10
北京时间·🕒 发布 18:08:53时区推断·⟳ 抓取 18:13:14·⚡ 决策 07-28 18:15:23 +2m09s·91.2 天前
翰森制药B7-H3 ADC瑞泽替康骨肉瘤III期达到PFS主要终点，但本条为已处理催化的媒体转述
瑞泽替康在复发骨肉瘤III期达到PFS主要终点，对翰森制药（03692.HK）的中国申报和GSK（GSK.US）的海外开发属于正向临床进展。
📄 原文Investing.com↗ 原文
Hansoh’s Ris-Rez meets primary endpoint in osteosarcoma trial
U.S. chip stocks extend losses on AI financing, China competition fears LONDON - Hansoh Pharmaceutical Group Co., Ltd.…
不做 翰森制药（03692.HK）
同一具体催化已在18:01由company_newsroom处理，本条Investing.com为重复转述且无新增临床、监管或商业化事实，不再推卡。
不做 GSK（GSK.US）
同一具体催化已处理且GSK为千亿美元级大市值公司，当前稿件未披露足以驱动市值级重定价的新增收入或监管里程碑，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 medium ↗
关键理由
- 瑞泽替康在复发骨肉瘤III期达到PFS主要终点，对翰森制药（03692.HK）的中国申报和GSK（GSK.US）的海外开发属于正向临床进展。
- 但近72小时已处理到同一具体催化的公司新闻源版本，当前Investing.com稿件未提供新增适应症、金额、监管或商业化信息。
主要风险
- 骨肉瘤适应症患者基数较小，短线重大性需要更多商业化定量支持。
反向证据
- 做多前查反向 · 来源 kb_search · 日期 2026-07-28 · 影响 none
内部KB仅命中近期创新药出海/ADC叙事与其他药企进展，未发现足以把重复转述升级为新交易卡的新增定量事实。
检索:翰森制药 Ris-Rez risvutatug rezetecan 骨肉瘤 B7-H3 ADC 销售 收入 GSK 授权
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 2,122 字
U.S. chip stocks extend losses on AI financing, China competition fears
LONDON - Hansoh Pharmaceutical Group Co., Ltd. announced today that its phase III trial ARTEMIS-011 evaluating risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma met its primary endpoint of progression-free survival, according to a press release statement from GSK plc (LSE/NYSE:GSK).
The trial, conducted in China, evaluated Ris-Rez in patients with osteosarcoma who progressed or relapsed after at least two prior lines of systemic therapy. The B7-H3-targeted antibody-drug conjugate demonstrated statistically significant improvements in progression-free survival compared with chemotherapy. The trial also showed consistent benefit across secondary endpoints, including overall survival.
The safety profile was consistent with prior findings in this tumor type, with no new safety signals identified. Hansoh Pharma will use the data for regulatory submission in China.
GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. The company is advancing EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. Ris-Rez has received US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma.
The results follow recently reported pivotal data in advanced or relapsed small-cell lung cancer. Ris-Rez is the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumor types.
Osteosarcoma is the most common primary bone cancer, accounting for 20-40% of all bone cancers. It is a rare bone cancer with a global incidence of approximately 3.4 cases per million people per year. Treatment options for patients with relapsed osteosarcoma are limited, with no approved therapies after patients progress on two prior lines of treatment.
GSK is developing Ris-Rez across multiple solid tumors, including lung cancer, prostate cancer and other solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LONDON - Hansoh Pharmaceutical Group Co., Ltd. announced today that its phase III trial ARTEMIS-011 evaluating risvutatug rezetecan (Ris-Rez) in relapsed osteosarcoma met its primary endpoint of progression-free survival, according to a press release statement from GSK plc (LSE/NYSE:GSK).
The trial, conducted in China, evaluated Ris-Rez in patients with osteosarcoma who progressed or relapsed after at least two prior lines of systemic therapy. The B7-H3-targeted antibody-drug conjugate demonstrated statistically significant improvements in progression-free survival compared with chemotherapy. The trial also showed consistent benefit across secondary endpoints, including overall survival.
The safety profile was consistent with prior findings in this tumor type, with no new safety signals identified. Hansoh Pharma will use the data for regulatory submission in China.
GSK holds exclusive global rights to develop Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan. The company is advancing EMBOLD Sarcoma-202, a global phase Ib/II trial of Ris-Rez in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma. Ris-Rez has received US FDA Breakthrough Therapy Designation in relapsed or refractory osteosarcoma.
The results follow recently reported pivotal data in advanced or relapsed small-cell lung cancer. Ris-Rez is the only B7-H3-targeted ADC to deliver positive phase III outcomes across multiple tumor types.
Osteosarcoma is the most common primary bone cancer, accounting for 20-40% of all bone cancers. It is a rare bone cancer with a global incidence of approximately 3.4 cases per million people per year. Treatment options for patients with relapsed osteosarcoma are limited, with no approved therapies after patients progress on two prior lines of treatment.
GSK is developing Ris-Rez across multiple solid tumors, including lung cancer, prostate cancer and other solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。